Table 1b.
Clinical characteristics of patients undergoing double UCBT
| Characteristic | All | With ATG | Without ATG | p |
|---|---|---|---|---|
| N | 594 | 122 | 472 | |
| Number of centers | 87 | 38 | 75 | |
| Age, median (range), years | 42 (18–79) | 49 (18–74) | 41 (18–79) | 0.005 |
| Gender | 0.16 | |||
| Male | 297 (50%) | 54 (44%) | 253 (51%) | |
| Female | 297 (50%) | 68 (56%) | 229 (49%) | |
| Karnofsky/Lansky score | <0.001 | |||
| < 90 | 171 (29%) | 50 (41%) | 121 (26%) | |
| 90–100 | 423 (71%) | 72 (59%) | 351 (74%) | |
| Race | 0.02 | |||
| Caucasian | 371 (62%) | 86 (70%) | 285 (60%) | |
| African-American | 69 (12%) | 19 (16%) | 50 (11%) | |
| Asian/Pacific Islander | 49 (8%) | 6 (5%) | 43 (9%) | |
| Hispanic | 84 (14%) | 8 (7%) | 76 (16%) | |
| Native American | 4 (< 1%) | 0 | 4 (< 1%) | |
| Missing | 17 (3%) | 3 (2%) | 14 (3%) | |
| CMV status of recipient | 0.01 | |||
| Negative | 183 (31%) | 25 (20%) | 158 (33%) | |
| Positive | 397 (67%) | 95 (78%) | 302 (64%) | |
| Missing | 17 (3%) | 2 (2%) | 12 (3%) | |
| Disease | 0.006 | |||
| AML | 428 (72%) | 100 (82%) | 328 (69%) | |
| ALL | 166 (28%) | 22 (18%) | 144 (31%) | |
| Disease status at UCBT | <0.001 | |||
| Early | 278 (47%) | 46 (38%) | 232 (49%) | |
| Intermediate | 225 (38%) | 43 (35%) | 182 (39%) | |
| Advanced | 91 (15%) | 33 (27%) | 58 (12%) | |
| Donor-Recipient gender | 0.52 | |||
| (F,F)-M or (F,M)-M | 207 (35%) | 38 (31%) | 169 (36%) | |
| All other combinations | 343 (58%) | 76 (62%) | 267 (57%) | |
| Missing | 44 (7%) | 8 (7%) | 36 (8%) | |
| HLA-matching | 0.77 | |||
| 4/6 + 4/6 | 251 (42%) | 48 (39%) | 203 (43%) | |
| One 4/6 UCB unit | 134 (23%) | 29 (24%) | 105 (22%) | |
| No 4/6 UCB units | 209 (35%) | 45 (37%) | 164 (35%) | |
| Total nucleated cell dose, pre-cryo, median (range) × 107/kg | 5 (3–55) | 4 (3–31) | 5 (3–55) | 0.02 |
| Total nucleated cell dose, pre-cryo, × 107/kg | 0.17 | |||
| 3–5 | 268 (45) | 64 (52%) | 204 (43%) | |
| 5–8 | 190 (32) | 31 (25%) | 159 (34%) | |
| ≥ 8 | 47 (8) | 7 (6%) | 40 (8%) | |
| Missing | 89 (15) | 20 (16%) | 69 (15%) | |
| Conditioning Regimen | 0.002 | |||
| Myeloablative | 351 (59%) | 57 (47%) | 294 (62%) | |
| Reduced Intensity | 243 (41%) | 65 (53%) | 178 (38%) | |
| TBI used | 497 (83%) | 60 (49%) | 437 (93%) | <0.001 |
| GVHD prophylaxis | <0.001 | |||
| CNI + SIRO | 27 (5%) | 14 (11%) | 13 (3%) | |
| CNI + MMF | 535 (90%) | 96 (79%) | 439 (93%) | |
| CNI + MTX | 15 (3%) | 4 (3%) | 11 (2%) | |
| CNI ± other | 17 (4%) | 8 (6%) | 9 (2%) | |
| Year of UCBT | <0.001 | |||
| 2003–2008 | 188 (32%) | 58 (48%) | 130 (28%) | |
| 2009–2012 | 406 (68%) | 64 (52%) | 342 (72%) |
Abbreviations: UCBT = Umbilical Cord Blood Transplant; GVHD = graft-vs.-host disease; CNI = Calcineurin Inhibitor (either Cyclosporine or Tacrolimus); SIRO = Sirolimus; MMF = Mycophenolate mofetil; MTX = Methotrexate; COR = Corticosteroids (systemic).